STOCK TITAN

Definium Therapeutics (DFTX) director receives RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Definium Therapeutics director Crystal Roger received new equity awards as part of her compensation. She was granted 4,666 restricted stock units, each representing the right to receive one common share, and now holds 24,289 common shares after this award.

Roger was also granted a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with any remaining unvested portion vesting immediately before the company’s next annual meeting if it occurs within a year, subject to her continued service.

Positive

  • None.

Negative

  • None.
Insider CRYSTAL ROGER
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 19,188 $0.00 --
Grant/Award Common Shares 4,666 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 19,188 shares (Direct, null); Common Shares — 24,289 shares (Direct, null)
Footnotes (1)
  1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
RSUs granted 4,666 units Restricted stock units granted to director on June 11, 2026
Shares held after grant 24,289 shares Common shares directly held by Crystal Roger after RSU award
Stock options granted 19,188 options Stock option covering common shares granted on June 11, 2026
Option exercise price $24.11 per share Exercise price for 19,188-share stock option
Option expiration June 10, 2036 Expiration date of granted stock option
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting financial
"immediately prior to the Issuer's annual meeting following the date of grant"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CRYSTAL ROGER

(Last)(First)(Middle)
C/O DEFINIUM THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, SUITE 8500

(Street)
NEW YORK NEW YORK 10007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares06/11/2026A4,666(1)A$024,289D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.1106/11/2026A19,188 (2)06/10/2036Common Shares19,188$019,188D
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Mark Sullivan, Attorney-in-Fact for Roger Crystal06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Definium Therapeutics (DFTX) disclose for Crystal Roger?

Definium Therapeutics reported that director Crystal Roger received equity awards consisting of restricted stock units and a stock option. These compensation-related grants increase her equity stake and align her interests with common shareholders through future share ownership, subject to vesting conditions.

How many restricted stock units did Crystal Roger receive from Definium Therapeutics (DFTX)?

Crystal Roger received 4,666 restricted stock units from Definium Therapeutics. Each RSU represents a contingent right to receive one common share, subject to vesting. This award adds to her existing holdings and forms part of her overall director compensation package in equity.

What are the terms of Crystal Roger’s new stock option at Definium Therapeutics (DFTX)?

Crystal Roger received a stock option for 19,188 common shares with an exercise price of $24.11 per share, expiring June 10, 2036. The option vests in 12 equal monthly installments, with potential acceleration before the next annual meeting if conditions are met.

How do Crystal Roger’s RSUs at Definium Therapeutics (DFTX) vest?

Crystal Roger’s 4,666 RSUs vest in monthly installments, with 1/12 of the underlying shares vesting on each monthly anniversary of the grant. If the next annual meeting occurs within a year, any remaining unvested RSUs vest immediately before that meeting, subject to continued service.

How many Definium Therapeutics (DFTX) common shares does Crystal Roger hold after this Form 4?

After the reported RSU grant, Crystal Roger directly holds 24,289 common shares of Definium Therapeutics. This figure reflects her ownership following the acquisition reported in the Form 4 and excludes any additional shares that could be obtained by exercising her stock option.

Are Crystal Roger’s new equity awards at Definium Therapeutics (DFTX) routine compensation?

The Form 4 describes Crystal Roger’s transactions as grants or awards of RSUs and stock options, indicating compensation-related acquisitions rather than open-market trades. Such awards are commonly used to compensate directors and link their incentives to long-term shareholder value.